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Abstract 
Stimuli that elicit itch are detected by sensory neurons that innervate the skin. This information is 
processed by the spinal cord; however, the way in which this occurs is still poorly understood. 
Here we investigated the neuronal pathways for itch neurotransmission, in particular the 
contribution of the neuropeptide somatostatin. We find that in the periphery, somatostatin is 
exclusively expressed in Nppb neurons, and we demonstrate that Nppb/somatostatin-cells 
function as pruriceptors. Employing chemogenetics, pharmacology and cell-specific ablation 
methods, we demonstrate that somatostatin potentiates itch by inhibiting inhibitory dynorphin 
neurons, which results in disinhibition of GRPR neurons. Furthermore, elimination of 
somatostatin from primary afferents and/or from spinal interneurons demonstrates differential 
involvement of the peptide released from these sources in itch and pain. Our results define the 
neural circuit underlying somatostatin-induced itch, and characterize a contrasting anti-
nociceptive role for the peptide. 
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Introduction 
The somatosensory system helps us evaluate our environment, for instance alerting us to 
harmful or potentially damaging conditions. Through this system noxious stimuli generate itch 
and pain percepts. The sensation of itch, which warns us to the presence of organisms or 
substances on or in the skin, triggers removal of these agents. In contrast, painful stimuli produce 
immediate escape to prevent tissue damage. The presence of painful and itch-inducing stimuli is 
detected by sensory neurons with cell bodies in the dorsal root ganglion (DRG) or trigeminal 
ganglion. These nociceptive and pruriceptive neurons transmit signals to the dorsal horn of the 
spinal cord or spinal trigeminal nucleus.  
Many different agents elicit itch and it is thought that these are detected by specific 
populations of pruriceptive primary afferent neurons1. One class, those that express the MrgA3 
receptor, are likely dedicated for the detection of pruritogens2. Another population expresses the 
neuropeptide Nppb, and since Nppb is necessary for itch behavior, it has been suggested that 
these neurons also function as pruriceptors3. Nppb is thought to transmit signals from peripheral 
afferents to cells in the dorsal horn that express Npr1 (the receptor for Nppb)3. Upon activation, 
these neurons are believed to release GRP, which in turn activates interneurons that express 
GRPR4. Npr1- and GRPR-expressing interneurons are both selectively required for itch 
sensation, suggesting a specific neuronal circuit for itch3,5.  
Recently, molecular approaches have started to uncover mechanisms for somatosensory 
information processing in the spinal cord6, and these reveal that the dorsal horn is a site of 
considerable integration of sensory signals7-11. Itch can be suppressed by other sensory inputs 
(counter-stimuli), e.g. biting or scratching, and this seems to involve modulation within the 
dorsal horn. The neurons that mediate the suppression of itch by counter-stimulation are thought 
to include a group of inhibitory cells known as B5-I neurons, because they depend on expression 
of the transcription factor Bhlhb5. Mice lacking B5-I neurons show exaggerated itch responses, 
suggesting that itch is inhibited by tonic or feedforward input from these cells12. The B5-I 
neurons, which account for around one third of inhibitory interneurons in the superficial dorsal 
horn, can be subdivided into two populations: those that express the neuropeptides dynorphin 
and galanin, and those that contain neuronal nitric oxide synthase (nNOS)13-15. Dynorphin 
inhibits itch, suggesting that B5-I neurons may suppress itch at least partly through 
dynorphin/kappa opioid receptor (KOR) signaling. However, Duan et al recently concluded that 
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dynorphin-expressing spinal cord neurons were not involved in suppressing itch9. There is 
therefore doubt about which cells are responsible for B5-I-mediated itch suppression. 
The inhibitory neuropeptide somatostatin is expressed in a small population of DRG 
neurons16. Transcriptomic studies indicate that these correspond to cells that express Nppb, 
together with several itch-related genes17,18 and it has recently been reported that ablation of 
somatostatin-expressing primary afferents caused itch deficits19. Intriguingly, intrathecal 
administration of somatostatin elicits scratching behavior15 hinting that it may be involved in 
enhancing itch. There are conflicting reports suggesting that somatostatin can either promote or 
attenuate pain20-24. As well as being present in primary afferents, somatostatin is expressed by 
many dorsal horn excitatory interneurons25 and these are important elements for transmission of 
mechanical pain9,26. Therefore, there is considerable uncertainty about the roles of somatostatin 
in itch and pain.  
Here we have used multiple approaches to examine how itch sensation can be modulated 
by somatostatin. Using optogenetics we demonstrate that sensory neurons expressing 
somatostatin and Nppb function as pruriceptors, and we show that somatostatin potentiates 
scratching evoked by GRP, Nppb, and histamine. By using chemogenetics to interrogate subsets 
of B5-I neurons, we establish that Sst2a-expressing dynorphin cells are the route through which 
somatostatin enhances itch. Employing specific lesioning techniques, we show that the 
disinhibition involving dynorphin cells operates at the level of the GRPR neurons, and we thus 
define the complete micro-circuit through which somatostatin modulates itch. Lastly, we 
generated and characterized cell type-specific conditional somatostatin knockout mice, and used 
these to reveal that somatostatin released from both primary afferents and spinal cord 
interneurons is required for normal itch behavior. These experiments also establish that 
somatostatin released from peripheral, but not spinal neurons, plays a critical role in suppressing 
heat pain.   
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Results 
Somatostatin and Nppb are co-expressed in a subset of DRG neurons  
Neuropeptides are known to serve various somatosensory signaling roles27. We recently 
studied the neuropeptides, NMB and Nppb, and demonstrated that they are involved in pain and 
itch mechanisms, respectively3,28. In addition to NMB and Nppb, there are many other 
neuropeptides expressed in DRG. To characterize these in greater detail we compared the 
expression profiles of several neuropeptides (Figures 1A and S1). Notably, the expression pattern 
of somatostatin is very similar to that of Nppb (Figure 1A) and single cell transcriptomic 
analyses suggest that they are co-expressed17,18,29. To determine the extent of overlap in 
expression of these neuropeptides, we performed double-label in situ hybridization (ISH). Figure 
1B shows that there was virtually complete co-expression (99% overlap: 161/163 Sst/Nppb-
neurons). This raised questions of how these neuropeptides are used by the same neuron, and 
what is the function of these neurons.  
 
Optogenetic activation of somatostatin-expressing primary afferent neurons elicits itch-
behavior  
Previously, we demonstrated that Nppb is both necessary and sufficient to produce itch 
behavior3, suggesting that Nppb/somatostatin neurons function as pruriceptors. The tight 
correspondence in gene expression of somatostatin and Nppb allowed us to test this by 
genetically manipulating these neurons in mice in which Cre is knocked into the somatostatin 
locus (SstCre), as was performed recently19. We first investigated whether Cre mediates 
appropriate reporter expression in SstCre mice. Double-label ISH analysis of tissue from reporter-
crossed mice (SstCre;Ai9) demonstrates that the majority of reporter-labeled neurons co-express 
Nppb (Figure S2A; 107/139 tdT-labeled neurons are Nppb-positive) and fibers from these 
neurons innervate the skin (Figure S2B). This indicates that SstCre marks the majority of 
somatostatin-expressing primary afferents. The rodent cheek itch model is widely used to 
distinguish itch and pain behaviors, and we adapted this by replacing pruritogen injection with 
optogenetic stimulation. We expressed channelrhodopsin (ChR2) in somatostatin neurons 
(SstCre;Ai32 mice). To ensure that ChR2 was not expressed in MrgA3 pruriceptors2, we analyzed 
co-expression of ChR2 with both Nppb and MrgA3 (Figure 2A). We found that the majority of 
Cre-mediated expression (of ChR2) was restricted to Nppb-positive neurons (130 of 176). In 
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addition, almost no MrgA3-expressing neurons co-expressed ChR2 (1 of 176). This confirms 
that the Nppb- and MrgA3-expressing neurons are separate populations17,18,29. To establish that 
somatostatin neurons can be optogenetically activated and determine the frequency they can 
follow, we initially measured responses to light in isolated sensory neurons (Figure S2C). 
Somatostatin neurons could follow optogenetic activation up to 20 Hz, and we used this 
frequency for behavioral assays. We activated the ChR2-expressing somatostatin neurons 
through a light cannula surgically implanted within 1mm of the dorsal surface of the trigeminal 
ganglion (Figure 2B). Remarkably, optogenetic activation produced robust scratching responses 
localized to the ipsilateral cheek (Figure 2C). Responses to optogenetic stimulation were similar 
to those induced by injection of histamine into the cheek, except that optogenetic stimulation 
only elicited scratching, while histamine also evoked cheek wipes. We observed almost no 
scratching of the contralateral cheek, and no behavioral responses to illumination with a non-
activating wavelength of light. These results demonstrate that activating somatostatin afferents is 
sufficient to generate selective itch behavior.  
 
Somatostatin interacts with both Nppb and GRP in itch signaling 
Our optogenetic experiments showed that itch can be induced by activation of 
somatostatin-expressing primary afferents, suggesting that somatostatin released from these cells 
acts as an itch transmitter. However it is unclear how somatostatin interacts with the itch 
transmitters Nppb and GRP3,4. A simple model would posit that the three neuropeptides interact 
in such a way as to have additive effects on itch. To investigate this we measured scratching 
elicited by Nppb and GRP alone, and compared the responses with those elicited by Nppb and 
GRP co-administered with the somatostatin receptor agonist octreotide. Furthermore, we 
compared Nppb- and GRP-induced scratching with that evoked by co-administration of Nppb or 
GRP together with the specific somatostatin Sst2 receptor antagonist CYN 154806. We predicted 
that if somatostatin is a transmitter involved in GRP- and Nppb-induced itch, then octreotide 
would increase scratching induced by these neuropeptides, while CYN 154806 would have the 
opposite effect. Indeed, we found that octreotide potentiated Nppb- and GRP-induced itch 
behavior, whereas CYN 154806 attenuated these responses (Figure 3A, B). CYN 154806 also 
attenuated histamine-induced itch behavior, as would be expected if somatostatin has a 
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physiological role in itch (Figure 3C). This indicates that somatostatin, GRP and Nppb are 
transmitters in a connected itch circuit.  
 
Spinal inhibition of itch involves the dynorphin subset of B5-I neurons 
Previously, somatostatin was shown to hyperpolarize B5-I interneurons, and the itching 
caused by intrathecal octreotide was absent in mice lacking these neurons15. This led to the 
suggestion that somatostatin-induced itch was mediated by disinhibition involving these cells. 
However, it was subsequently reported that B5-I neurons are not involved in itch behavior9. 
Furthermore, B5-I neurons can be subdivided into two populations, which show only limited 
(~20%) overlap, based on expression of dynorphin and nNOS13,15, and it was not clear which of 
these was involved in modulating itch. We therefore investigated which type of B5-I neurons is 
required for pruritogen- and somatostatin-induced itch by manipulating the activity of either 
dynorphin- or nNOS-neurons. We engineered mice in which we could individually interrogate 
these populations, based on expression of designer receptors exclusively activated by designer 
drugs (DREADDs)30 (Figure 4A). Specifically, we injected AAV coding for Cre-dependent Gq-
coupled DREADD hM3Dq (DREADDq) fused to mCherry into one side of the lumbar dorsal 
horn31 of PdynCre and nNOSCreERT2 mice (Figure 4B). Importantly, we found that AAV-infection 
resulted in expression of mCherry in the appropriately targeted populations, and that 
chemogenetic activation of neurons with clozapine-N-oxide (CNO) caused Fos expression in the 
majority (92-95%) of mCherry-positive cells, confirming that both populations were activated 
(Figure 4B-D, Figure S3). In both genotypes mCherry-positive cells were most numerous in 
laminae I-II and scattered through deeper laminae, consistent with the distribution of cells that 
express nNOS and preprodynorphin (PPD). nNOS-cells can be readily detected with 
immunocytochemistry and we confirmed that in nNOSCreERT2 mice, 429/431 (99.5%) of the 
mCherry-expressing cells in laminae I-II were nNOS-immunoreactive. Since both nNOS and 
dynorphin are also expressed in some excitatory interneurons, we confirmed expression of 
mCherry and Fos in inhibitory interneurons by immunostaining for the transcription factor Pax2 
and/or the Sst2a receptor, both of which are restricted to inhibitory interneurons in this 
region15,31,32. Close to the injection sites in the nNOSCreERT2 mice, mCherry was present in 71.8% 
(range 58.8-91.7%) of Sst2a+ (inhibitory) nNOS-cells. In the PdynCre mice 44% (range 33.8-
50.8%) of cells that contained both Pax2 and Sst2a were mCherry-positive, and since PPD is 
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present in 54% of Sst2a+ neurons in laminae I-II13, we estimate that 82% of inhibitory dynorphin 
cells expressed DREADDq in this region. We also confirmed that the DREADDq was not 
expressed in primary afferents, by examining ipsilateral L4 DRGs (4 mice of each genotype) and 
observing that there were no mCherry-immunoreactive neurons in any of these ganglia (Figure 
S4).  
If somatostatin induces itch by a disinhibitory mechanism involving B5-I neurons, we 
would expect that chemogenetic activation of one or both of these populations would attenuate 
pruritogen-evoked itch behavior by increasing inhibitory tone. Consistent with this prediction, 
we found that activation of dynorphin-neurons with CNO markedly attenuated itch responses to 
the itch-inducing agent chloroquine injected intradermally into the ipsilateral calf (Figure 4E and 
Figure S4). In contrast, activation of nNOS-neurons had no effect on pruritogen-induced itch 
(Figure 4E). Furthermore, in a separate series of experiments involving PdynCre mice, we tested 
the effect of intrathecal administration of AAV coding for DREADDq on itch behavior in 
response to pruritogens injected into the nape of the neck. Administration of CNO to activate the 
dynorphin neurons attenuated both histamine- and chloroquine-evoked itch. Notably scratching 
evoked by intrathecal administration of octreotide was also attenuated when the dynorphin 
neurons were activated by CNO (Figure 4F), consistent with the suggestion that somatostatin 
induces itch by a disinhibitory mechanism involving the dynorphin-neurons.  
Since activation of nNOS-neurons did not alter itch behavior, we investigated their 
function by testing other somatosensory modalities. Additionally, we wondered whether, as well 
as their anti-pruritic role, dynorphin neurons could modulate responses to other stimuli. We 
therefore examined behavioral responses to noxious thermal and mechanical stimulation 
following chemogenetic activation of dynorphin and nNOS-neurons in lumbar dorsal horn. 
Interestingly, activation of nNOS-neurons decreased sensitivity to both noxious heat and 
mechanical stimuli (Figure 5A, B), suggesting that they have an anti-nociceptive, but not an anti-
pruritic, role. Surprisingly, we found that as well as inhibiting itch, chemogenetic activation of 
dynorphin neurons markedly increased sensitivity to von Frey hairs, although it had no effect on 
responses to heat stimulation (Figure 5A, B). This pro-nociceptive effect is likely mediated 
through activation of dynorphin-expressing excitatory interneurons, as these consistently showed 
Fos expression after treatment with CNO, and included vertical cells (Figures S3A, S5A), which 
are thought to innervate nociceptive projection neurons in lamina I33. Interestingly, we noticed 
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that mCherry-labelled excitatory cells were particularly numerous in the medial third of the 
dorsal horn, where they accounted for ~50% of the mCherry population, whereas they only 
constituted 12% of mCherry cells elsewhere in the superficial laminae. We recently reported that 
PPD-expressing excitatory neurons are concentrated in the medial part of laminae I-II in the L4 
segment, suggesting an association with regions innervated by glabrous skin13. To confirm this, 
we immunostained sections through lumbar and cervical enlargements of wild-type mice and 
compared the distribution of inhibitory (Pax2+) and excitatory (Pax2-) PPD-immunoreactive 
neurons. In both enlargements, the excitatory cells were largely restricted to glabrous skin 
territory, identified by lack of input from VGLUT3-expressing C-low threshold 
mechanoreceptors, which are restricted to hairy skin34 (Figure 5C-G and Figure S5B, C). It is 
therefore likely that excitatory dynorphin neurons are largely restricted to regions of dorsal horn 
innervated by glabrous skin, and that they accounted for the mechanical hyperalgesia that we 
observed when von Frey hairs were applied to the plantar surface of the foot. The calf itch model 
activates cells in the middle third of the superficial dorsal horn within the L3 segment35. 
Excitatory PPD cells were rarely present in this region (Fig 5C-G), and are therefore unlikely to 
be involved in the anti-pruritic effect seen in the CNO-treated mice.  Together, these results 
establish that dynorphin- and nNOS-containing interneurons modulate responses to several 
sensory modalities and produce distinct behavioral effects. 
 
Somatostatin and dynorphin interact with Nppb signaling at the level of GRPR neurons 
Previously it was reported that dynorphin can attenuate itch through the KOR and that 
KOR antagonists can induce itch15. However, it is unclear how dynorphin acting on KORs 
modulates the itch evoked by somatostatin and Nppb. To examine this, we again took a 
pharmacological approach to determine the sequence in the itch pathway involving these 
neurotransmitters. First, our results place dynorphin downstream of somatostatin (Figure 4F), 
therefore we reasoned that the KOR agonist ICI199441 should block scratching responses 
induced by octreotide15. Second, it follows that if the somatostatin receptor is upstream of the 
action of KOR, we would predict that administration of somatostatin receptor antagonist would 
not affect itch induced by the KOR antagonist norbinaltrorphimine. Lastly, since peripherally 
induced itch is inhibited by KOR agonist, then scratching evoked by histamine and Nppb should 
also be attenuated by KOR agonist15. As expected, we found that KOR agonist attenuated 
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somatostatin-induced itch, that KOR antagonist-induced itch was unaffected by somatostatin 
receptor antagonist, and that both histamine- and Nppb-induced itch were also attenuated by 
KOR agonist (Figure 6A, B). Together these results further substantiate the pathway for 
somatostatin-induced itch, through disinhibition involving the dynorphin subset of B5-I neurons, 
and provide additional evidence that this pathway interacts with Nppb signaling. 
Our results indicate that somatostatin-induced itch is mediated through disinhibition 
involving dynorphin-expressing interneurons, and that somatostatin can potentiate Nppb 
signaling. However, the site of interaction between these pathways is unknown. This could be at 
the level of either Npr1-neurons, or GRPR-neurons. To investigate this, we used conjugated 
toxins to generate selective lesions in the Nppb and GRP pathways3,5 and we pharmacologically 
blocked GRPR. Specifically, we used Nppb-saporin and GRP-saporin to ablate Npr1- and 
GRPR-expressing dorsal horn neurons, respectively, and we inhibited GRPR with GRPR 
antagonists. By exploiting octreotide- and KOR antagonist-triggered itch behavior, we could 
then examine the requirement of Nppb and GRP neurons for these types of itch. We reasoned 
that a block at the site of intersection would attenuate itch-responses while a block upstream of 
this site would not. As expected, we found that one population of neurons was required: ablation 
of GRPR neurons, and treatment with GRPR antagonist, profoundly reduced the itch elicited by 
both octreotide and KOR antagonist, as well as that evoked by histamine (Figure 6C-E). In 
contrast, elimination of Npr1 neurons attenuated histamine-induced itch, but had no effect on 
octreotide- and KOR antagonist-evoked itch, suggesting that somatostatin and dynorphin act 
downstream of Npr1-cells (Figure 6F-H). Together these data suggest a model for somatostatin-
mediated itch that involves the dynorphin subset of B5-I neurons, which suppress transmission at 
the level of the GRPR cells (Figure 6I). 
 
Somatostatin is required for normal itch and pain responses 
Our findings suggest that the itch-inducing effect of somatostatin is mediated at least in 
part by dynorphin neurons. However, the origin of the somatostatin that acts on these neurons to 
cause itch is unknown. Somatostatin is expressed by both primary afferents and excitatory spinal 
cord interneurons 25,36. Either or both of these populations might be the source of the 
somatostatin that is involved in regulating itch. To address this issue, and provide further 
evidence that somatostatin acts as a mediator of itch in vivo, we generated mice in which 
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somatostatin could be eliminated in specific cell-types (Figure 7A). The resulting Sstf/f mice were 
crossed with Trpv1cre, Lbx1 cre, and Wnt1 cre lines to eliminate somatostatin from DRG neurons, 
dorsal horn neurons, and both classes of neurons, respectively. The resulting mice were born at 
expected Mendelian ratios, appeared healthy, and showed none of the phenotypic abnormalities 
present in global somatostatin knockout mice37. ISH confirmed selective loss of somatostatin 
mRNA in the expected tissues (Figure 7B). Our results from blocking the somatostatin receptor 
(Figure 3) led to the prediction that mice lacking somatostatin in the dorsal horn should display 
reduced responses to itch-inducing agents. To test this, we assessed behavioral responses of the 
mutant mice to several pruritogens. As anticipated, we found that mice lacking somatostatin in 
both peripheral and spinal cord neurons (Sstf/f;Wnt1 cre), exhibited significant itch deficits to all 
pruritogens tested (Figure 7C). In contrast, mice lacking somatostatin in either primary afferents 
(Sstf/f;Trpv1 cre), or dorsal horn interneurons (Sstf/f;Lbx1 cre), displayed itch behavior similar to 
that of control littermates (Figure S6AB). These results provide further evidence that 
somatostatin is required for itch transmission in vivo and show that somatostatin from both 
primary afferents and spinal cord interneurons contributes to normal itch behavior.  
The finding that somatostatin released from interneurons is required for normal itch 
transmission led us to search for further evidence supporting such a role. We investigated 
PdynCre mice that had received spinal injections of AAV coding for Cre-dependent enhanced 
green fluorescent protein (eGFP), to allow visualization of dynorphin neurons. We identified 
eGFP+ cells with tonic or transient firing patterns (characteristic of inhibitory neurons38) and 
found that all of these cells (8/8) were hyperpolarised by bath-applied somatostatin (Figure S7), 
consistent with expression of Sst2a receptor by 91% of inhibitory dynorphin cells13. In anatomical 
studies, axonal boutons belonging to somatostatin-expressing interneurons can be recognized by 
their co-expression of somatostatin and VGLUT2, whereas somatostatin primary afferent 
terminals have very low or undetectable levels of VGLUT2-immunoreactivity36. We found, as 
expected, that most eGFP+ cell bodies in superficial dorsal horn (78%) were Sst2a-
immunoreactive, and that these lay within a dense plexus of boutons that contained both 
somatostatin and VGLUT2, and therefore presumably originated from local somatostatin 
interneurons. In addition, all of the cells examined had numerous contacts from 
somatostatin+/VGLUT2+ boutons on their cell bodies and dendrites (Figure S8). These findings 
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suggest that somatostatin released from axons of local interneurons acts on dynorphin-expressing 
inhibitory interneurons to cause disinhibition. 
In addition to a role in itch, somatostatin has been proposed to be either pronociceptive22-
24 or analgesic39,40. To investigate this, we tested the nociceptive behavior of conditional Sstf/f 
mice. Intriguingly, we found that mice lacking somatostatin in DRG-neurons (Sstf/f;Trpv1 cre), 
displayed dramatically increased sensitivity to noxious heat (Figure 8). In contrast, Sstf/f; Lbx1 cre 
animals exhibited normal responses to noxious heat, while Sstf/f;Wnt1 cre mice displayed 
responses similar to those of Sstf/f;Trpv1 cre mice. These results indicate that somatostatin 
released from primary sensory neurons normally suppresses nociceptive responses. This might 
result from effects in the spinal cord, or be due to tonic release of somatostatin from Nppb-
afferents acting on peripheral endings of nociceptive afferents, as reported previously20,21,41. 
Conditional Sstf/f mice also exhibit phenotypic differences in withdrawal thresholds to von Frey 
hairs (Figure S6C) suggesting a contribution of somatostatin to this behavior. Notwithstanding 
the mechanism involved, the phenotype of somatostatin-deficient mice demonstrates that 
somatostatin released from primary afferents contributes to the inhibition of pain.  
 
Discussion 
Here, using optogenetics, chemogenetics, pharmacology, and conditional genetic 
knockouts, we delineate roles for somatostatin in itch and pain sensation. First, using optogenetic 
activation, we show that sensory neurons that express somatostatin are sufficient to evoke itch 
behavior (Figure 2). Second, we demonstrate that somatostatin directly potentiates itch elicited 
by Nppb and GRP, and that a somatostatin receptor antagonist attenuates histaminergic itch 
(Figure 3). Third, genetic knockout of somatostatin establishes that it is required for normal itch 
behavior (Figure 7), and our studies define a disinhibitory spinal cord microcircuit through which 
somatostatin modulates itch (Figure 3, 4, and 6). Lastly, we show that somatostatin released from 
primary afferents is involved in inhibiting pain behavior (Figure 8). Therefore, our studies reveal, 
at both molecular and cellular levels, the mechanisms by which somatostatin modulates itch, and 
we show that somatostatin also plays an important role in heat nociception.  
The co-localization of somatostatin and Nppb in a subclass of sensory neurons raised the 
question of how these neuropeptides interact in itch processing. Our results reveal that they act 
on distinct neural substrates and that the pathways engaged by these transmitters, although 
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initially separate, converge and interact (Figure 3, 4, and 6).  Although somatostatin presumably 
acts at least partly through dynorphin/KOR signaling to regulate itch, inhibition involving 
GABA and glycine has also been shown to play a critical role in suppressing pruritogen-evoked 
activity31,42,43. GABA, the principal fast transmitter used by the dynorphin/galanin 
interneurons44, is therefore also likely to have contributed to the anti-pruritic effect of stimulating 
the dynorphin neurons, and to be involved in somatostatin-evoked itch. Since neuropeptides have 
a longer-lasting action than amino-acid transmitters, we suggest that peptidergic mechanisms 
involving somatostatin and dynorphin probably modify the excitability of neurons in the spinal 
cord to control longer-term behavioral responses, whereas fast transmitters underlie the rapid 
suppression of itch by counter-stimuli. Recently another study examined the effects of 
chemogenetic and optogenetic activation of spinal cord somatostatin neurons, and found that this 
potentiated mechanical sensitivity26 in line with the proposed role of these neurons in gating 
mechanical pain9. In addition, the authors reported that low-frequency optogenetic stimulation of 
these neurons increased histamine-evoked scratching behavior, and this effect was reduced by 
intrathecal administration of the somatostatin receptor antagonist CYN-154806 (250 ng)26, 
suggesting that it was mediated at least in part by somatostatin released from these cells. 
However, this finding is difficult to interpret, because we show here that intrathecal treatment 
with a somewhat higher dose (1 μg) of CYN-154806 strongly suppresses histamine-evoked itch 
(Figure 3C). Nonetheless, these findings are consistent with our conclusion that somatostatin 
release from the spinal cord contributes to itch neurotransmission. Previously we showed that 
somatostatin is expressed in the majority of GRP neurons45, and so co-release of GRP and 
somatostatin from these cells could independently contribute to itch.  
Molecularly defined classes of primary afferent neurons that detect and transmit signals 
for thermal, tactile and itch stimuli have been identified, and it has been suggested that sensation 
is primarily encoded by these specifically tuned receptor cells1. However, since somatostatin 
afferents express TRPV1, they could be activated by noxious stimuli. Nonetheless, our 
optogenetic findings show that selective stimulation of these cells results in itch, but not pain 
behaviors. This suggests that a coding mechanism allows these two types of stimulus to be 
distinguished. One potential mechanism would be the "leaky gate" model46. This proposes that 
although pruritic and nociceptive inputs converge on GRP neurons, frequency coding by these 
cells determines whether pain or itch behavior is evoked, through a feed-forward inhibition 
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involving enkephalinergic neurons. As predicted by this model, Sun et al46 found that ablation of 
GRP cells resulted in a dramatic reduction of itch and an increase in certain types of pain. 
However, their ablation appears to have extended beyond the GRP neurons, since they reported a 
marked loss of cells that express PKCγ, which shows minimal overlap with GRP45,47. Loss of 
additional populations of excitatory interneurons therefore complicates interpretation of their 
behavioral findings. Consistent with the idea that somatostatin/Nppb neurons are dedicated itch 
chemoreceptors, the IL31Ra itch receptor is exclusively expressed by these cells17,18,29,48. The 
somatostatin primary sensory neurons are molecularly distinct from MrgA3-neurons17,18 (Figure 
2) and therefore represent an additional population of pruriceptive afferents.  
 There has been great interest in determining the mechanisms by which circuits in the 
spinal cord integrate and modify incoming sensory signals. We studied the effects of activating 
dynorphin neurons, most of which represent a subset of B5-I cells. Consistent with the 
suggestion that B5-I cells include neurons responsible for suppressing itch15, and that KOR 
agonists act locally within the spinal cord to reduce itch (Figure 6 and reference 15), we found 
that chemogenetic activation of these neurons suppressed pruritogen-evoked itch behavior 
(Figure 4). Furthermore, in line with the view that somatostatin-induced itch is mediated through 
a disinhibitory mechanism, activating the dynorphin neurons also attenuated scratching evoked 
by intrathecally administered octreotide (Figure 4F). This anti-pruritic role was specific for the 
dynorphin neurons, since activating the other main class of B5-I cells, those that express nNOS, 
reduced responses to noxious stimuli but had no effect on itch behavior. 
Previously, Duan et al reported that dynorphin-expressing spinal cord neurons have a role 
in gating mechanical pain, since mice lacking dynorphin-lineage neurons were hypersensitive to 
mechanical stimulation, but showed normal itch behavior9. These studies used the same PdynCre 
line, however, our experimental approach differed significantly from that of Duan et al. We 
engineered mice in which mature dynorphin neurons express DREADDq, whereas Duan et al 
used an intersectional ablation strategy. This would have captured inhibitory interneurons that 
transiently express dynorphin13, but apparently excluded excitatory dynorphin cells, as well as 
~40% of the galanin-expressing inhibitory neurons (see Figures 5 and S7 of Duan et al). Because 
of these differences, the neurons we activated only partially overlap with those that they ablated. 
This presumably accounts for the difference in our findings with mechanical pain tests, and also 
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for the discrepancy between the anti-pruritic effect that we observed and the lack of a significant 
effect on itch reported in their study. 
Our findings reveal that somatostatin is also important in controlling pain (Figure 8). In 
particular, they suggest that somatostatin released from primary afferents tonically suppresses 
responses to noxious heat. This resolves previous conflicting reports, which suggested that 
somatostatin could either promote or attenuate pain20-24. It has long been known that activity in 
pain pathways can suppress itch49. Intriguingly, our findings suggest that somatostatin released 
by pruriceptive primary afferents suppresses pain, meaning that itch may also inhibit pain. 
The activity in pruriceptors in the skin is conveyed via the spinal cord to the brain, where 
the perceptual quality of itch is produced. By investigating the function of somatostatin in spinal 
processing, we show that it plays important roles in transmitting and integrating sensory 
information. In particular, we demonstrate a mechanism whereby two neuropeptides, 
somatostatin and Nppb, that are released from the same primary afferent co-operate in a 
modality-specific dorsal horn circuit that underpins the evolutionarily important sensation of 
itch.  
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Figure Legends 
Figure 1: Somatostatin is co-expressed with Nppb in DRG neurons.  
A, in situ hybridization of sections through DRG shows that different neuropeptides are 
expressed in subsets of sensory neurons; SST, somatostatin, Nppb, natriuretic polypeptide B, 
NMB, neuromedin B, CGRP, calcitonin gene related peptide. B, double label ISH reveals that 
somatostatin-expressing neurons (magenta) co-express the neuropeptide Nppb (green). Similar 
results were obtained from 3 mice. 
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Figure 2: Somatostatin-expressing primary afferent neurons are sufficient to trigger itch-
behavior.  
A, triple label ISH reveals that in SstCre;Ai32 mice expression of ChR2-YFP (green) occurs 
largely in Nppb-neurons (red). MrgA3-neurons (blue) are separate from both Nppb and ChR2-
YFP positive neurons. Similar results were obtained from 3 mice. B, schematic diagram 
illustrating the strategy employed to optogenetically activate trigeminal ganglion somatostatin-
expressing neurons that innervate the face. The implanted fiber optic cannula (indicated as an 
outlined blue line) was passed through the brain to a position approximately 1 mm dorsal to the 
TG and fixed in place with dental cement. C, unilateral optogenetic activation of the trigeminal 
ganglion of SstCre;Ai32 animals with 470 nm illumination generated similar numbers of scratch 
bouts to that elicited by intradermal administration of histamine (100 µg), but did not induce 
scratching of the contralateral cheek. In addition, while optogenetic stimulation of Sst cre;Ai32 
neurons did not evoke cheek wipes, histamine injection elicited 6.2 wipes ± 1.53 (mean ± SEM). 
Activation with 590 nm light evoked minimal scratching bouts. Significant differences were 
assessed using one-way repeated measure ANOVA with post hoc Sidak tests (t 
F2,16 = 3.139, *p=0.0001 for both comparisons). Data represent means ±SEM (n=5 animals 
optogenetic experiments and n=7 histamine cheek assay C57BL/6 mice). 
 
Figure 3: Modulation of Nppb- and GRP-induced itch responses by somatostatin receptor 
agonist and antagonist.  
Scratching bouts induced by intrathecal administration of: A, Nppb (5 µg), octreotide (10 ng), a 
combination of Nppb and octreotide, or Nppb and the somatostatin agonist CYN154806 (1 µg); 
B,  GRP (1 nmole), octreotide (10 ng), a combination of GRP and octreotide (10 ng), or GRP and 
CYN154806 (1 µg); C, histamine (100 µg), or a combination of histamine and CYN154806 (1 
µg) revealed that Nppb- and GRP-evoked itch behavior is significantly potentiated by octreotide 
and attenuated by CYN154806 (A, B). In addition, CYN154806 significantly attenuated 
histamine induced scratching. Significant differences for A and B were assessed using one-way 
ANOVA with post hoc Sidak tests: Octreotide induced scratching was significantly changed by 
the addition of Nppb (*p= 0.0002) and Nppb elicited scratching was significantly reduced by 
CYN (*p=0.0053), F3,19 = 0.6796. Octreotide induced scratching was significantly changed by 
the addition of GRP (*p= 0.0001) and GRP elicited scratching was significantly reduced by 
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CYN (*p= 0.0036) F3,20 = 0.5998. Data represent means ± SEM (n= 6, 5, 6, 6, 6, 6, 6, and 6). 
Significant differences for C were assessed using two-sided unpaired Student's t-test (*p= 0.002). 
Data represent means ± SEM (n= 9 and 8). 
 
Figure 4: Spinal cord dynorphin neurons modulate itch and are downstream of the site of action 
of somatostatin.  
A, schematic diagram of the viral-based strategy employed to chemogenetically activate spinal 
cord neurons expressing dynorphin or nNOS. B, sagittal sections stained for mCherry showing 
that intraspinal injection of the AAV in PdynCre and nNOSCre mice produced expression with the 
expected distribution in spinal cord segments L3-L5, which innervate the hind-limb including the 
calf. Scale = 200 μm. C, Chemogenetic activation in the PdynCre mouse. A transverse section of 
spinal cord taken from a PdynCre mouse that had been injected with AAV2-flex-hM3Dq-
mCherry and treated with CNO 2 hours prior to perfusion fixation. The section was 
immunostained to reveal mCherry (mCh, red), the somatostatin receptor Sst2a (blue), Pax2 (gray) 
and Fos (green). Asterisks (*) show the cell bodies of 3 neurons that express hM3Dq-mCherry, 
Sst2a receptor, Pax2 and Fos, indicating chemogenetic activation of inhibitory (Sst2a-expressing) 
dynorphin cells. Similar results were obtained in experiments on 3 CNO-treated animals (see 
Figure S3 for numbers). Arrowhead points to a Pax2+ (inhibitory) Sst2a-expressing neuron that 
lacks mCherry and this cell was not Fos-positive. Scale = 10 μm. D, Chemogenetic activation in 
the nNOSCreERT2 mouse. Transverse section of spinal cord taken from a nNOSCreERT2 mouse 
injected with AAV2-flex-hM3Dq-mCherry and treated with CNO 2 hours prior to perfusion 
fixation. The section was immunostained to reveal mCherry (red), Sst2a (blue), nNOS (gray) and 
Fos (green). Five cells showing varying levels of nNOS-immunoreactivity are visible. Two of 
these (asterisks) are stained for mCherry and Sst2a (inhibitory nNOS cells) and these are Fos-
positive. Of the 3 cells with weak nNOS-immunoreactivity, one (arrow) is positive for mCherry 
and Fos, but lacks Sst2a, and is therefore likely an excitatory interneuron. The other two are not 
labelled with either mCherry or Fos: one of these is an Sst2a -positive inhibitory neuron (single 
arrowhead), while the other lacks Sst2a and is therefore likely to be an excitatory neuron (double 
arrowhead). This shows chemogenetic activation of nNOS cells, including inhibitory (Sst2a-
expressing) interneurons. Similar results were obtained in experiments on 3 CNO-treated animals 
(see Figure S3 for numbers). Scale = 20 μm. E. The time spent biting the calf in response to 
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intradermal injection of chloroquine (100 μg) was reduced following chemogenetic activation 
(CNO) in PdynCre mice, but there was no effect on itch responses in nNOSCreERT2 animals. 
Significant differences were assessed using two-sided unpaired Student t-tests (t21 = 2.92, *p = 
0.0082; and t23 = 0.875, p = 0.391 ns not significant). Data represent means ± SEM (n=11, 12, 
12, and 13 animals, for PdynCre mice treated with CNO and vehicle and for nNOSCreERT2 mice 
treated with CNO and vehicle, respectively). mCherry-labelled injection sites (as shown in B) 
were verified in all of these experiments. F, DREADDq activation following intrathecal injection 
of AAV2-flex-hM3Dq significantly reduced numbers of itch bouts in PdynCre mice injected into 
the nape of the neck with histamine (100 µg) and chloroquine (100 µg), and also when octreotide 
(100 ng) was administered intrathecally. Significant differences were assessed using two-sided 
unpaired Student t-tests (t10 = 3.017, 3.053, 4.861, *p = 0.013, 0.0122, and 0.0007). Data 
represent means ± SEM (n= 6 animals).  
 
Figure 5: Chemogenetic activation of PdynCre and nNOSCreERT2 neurons modulates responses to 
heat and mechanical stimuli and the pro-nociceptive effect of dynorphin neuron activation likely 
involves excitatory interneurons.  
A, Hargreaves assays revealed that while responses to heat stimulation were unaffected in mice 
in which dynorphin neurons were chemogenetically activated (CNO), sensitivity was 
significantly reduced in animals in which nNOS neurons were activated. B, von-Frey tests 
showed that chemogenetic activation (CNO) of dynorphin neurons elicited mechanical 
hyperalgesia, while activation of nNOS neurons caused significantly reduced sensitivity to 
mechanical stimulation. In all cases behavioral results of testing the paw ipsilateral to spinal 
AAV injection in vehicle- and CNO-treated mice (post-surgery) were compared with results 
from the same animals obtained before intraspinal injection of the AAV (pre-surgery). 
Significant differences were assessed using 2-way ANOVA with post hoc Sidak tests (F1,25 = 
4.566, *p = 0.0117, F1,25 = 9.855, **p = 0.0039, F1,25 = 19.25, ***p = 0.000012). Data represent 
means ± SEM (n=13, 11, 14, and 13 animals, for PdynCre mice treated with CNO and vehicle and 
for nNOSCreERT2 mice treated with CNO and vehicle, respectively). C-G. Plots of the distribution 
of excitatory and inhibitory dynorphin-expressing cells show that the excitatory cells are highly 
concentrated in the region innervated from glabrous skin. C. Immunostaining for VGLUT3 was 
used to reveal the extent of innervation from hairy skin, since C-low threshold mechanoreceptors 
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(which express VGLUT3) are largely absent from glabrous skin. The VGLUT3 band occupies 
the whole mediolateral extent of the superficial dorsal horn at L3, but is absent from the medial 
part of the L4 and L5 segments, which are innervated by afferents from glabrous skin. The 
junction between these regions is marked (arrowheads). Similar results were obtained from 3 
mice. D The distribution of preprodynorphin (PPD)-immunoreactive cells that are inhibitory 
(Pax2-positive, blue circles) and excitatory (Pax2-negative, red circles) plotted onto outlines of 
the L3-L5 segments (data pooled from 3 mice). The junction between hairy and glabrous skin 
territories is marked by a dashed line. Note that excitatory PPD cells are concentrated in the 
glabrous skin territory, and are much less numerous in regions innervated from hairy skin, 
including the L3 segment. E-G. Examples of immunostaining for PPD (magenta), NeuN (blue) 
and Pax2 (green) in the medial (Med) and lateral (Lat) parts of the L3, L4 and L5 segments, 
respectively. Examples of Pax2-positive PPD-immunoreactive neurons are indicated with 
arrows, and some Pax2-negative PPD-immunoreactive cells are shown with arrowheads. Similar 
results were obtained from 3 mice. Scale bars C = 100 μm, E-G = 20 μm. 
 
Figure 6: Somatostatin acts upstream of dynorphin-expressing inhibitory neurons, which interact 
with the Nppb-itch pathway at the level of GRPR-neurons.  
A, itch-responses to intradermally injected histamine (100 µg), and intrathecally administered 
Nppb (5µg) and octreotide (100ng) were significantly attenuated when the kappa opioid receptor 
(KOR) agonist ICI199441 (100ng) was co-administered. Significant differences were assessed 
using two-sided unpaired Student t-tests (t9 = 7.059, t10 = 10.14, t9 = 11.78, *p = 0.0001 for all). 
Data represent means ± SEM (n= 6, 5, 6, 6, 5, and 6 animals). B, The somatostatin receptor Sst2 
antagonist CYN154806 (1 µg) does not affect itch-behavior induced by the kappa opioid 
receptor antagonist norBinaltrorphimine (100 µg), differences were assessed using two-sided 
unpaired Student t-tests (t12 = 2.708, ns p= 0.06). Data represent means ± SEM (n= 7 animals). C 
histamine (100 µg), D octreotide (100 ng), and E the kappa opioid receptor antagonist 
norBinaltrorphimine (100 µg) induced scratching bouts were reduced in mice treated with GRP-
saporin, or GRPR antagonist, significant differences were assessed using one-way ANOVA with 
post hoc Sidak tests (F2,15 = 42.48, F2,15 = 37.87, F2,16 = 29, *p = 0.0001 for all). Data represent 
means ± SEM (n= 6, 6, 6, 6, 6, 6, 6, 7, and 6 animals), Nppb-saporin (F-H) treatment reduced 
scratching bouts to histamine, but not to octreotide or norBinaltrorphimine, differences were 
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assessed using two-sided unpaired Student t-tests (t5 = 4.953, *p=0.004, t5 = 1.184, ns p= 0.29 
and t5 = 1.466,  p = 0.203). Data represent means ± SEM (n= 6 animals). I, schematic diagram of 
proposed model of the somatostatin-mediated itch microcircuit. Broken red arrows indicate 
incompletely defined pathways, and blue and green circles are neurons that are identified by 
either the receptor, or the neuropeptide(s) they express; Sst, somatostatin, Nppb, natriuretic 
polypeptide b, Npr1, Natriuretic polypeptide receptor 1, Sst2a, somatostatin receptor 2a, GRP, 
gastrin releasing peptide, and GRPR, gastrin releasing peptide receptor. 
 
Figure 7: Somatostatin-null mice exhibit itch-related behavioral deficits to pruritogens.  
A, schematic diagram depicting the genetic strategy employed to conditionally eliminate the 
expression of somatostatin. B, ISH of section through DRG (top row) and dorsal spinal cord 
(bottom row) demonstrates that Sstf/f;Trpv1 cre mice lack expression of somatostatin in DRG, 
Sstf/f;Lbx1 cre mice lack expression of somatostatin in the spinal cord, and that Sstf/f;Wnt1 cre mice 
lack expression of somatostatin in DRG and spinal cord. Similar results were obtained from 3 
mice. C, Sstf/f;Wnt1 cre mice are much less sensitive to intradermal injection of a variety of 
compounds that induce itch than normal littermate controls. Significant differences were 
assessed using two-sided unpaired Student t-tests (t10 = 4.082, t12 = 3.967, t10 = 2.83, t10 = 3.836, 
t13 = 2.368, t10 = 2.279, *p = 0.0022, 0.0019, 0.0179, 0.0033, 0.0034, and 0.0458). Data represent 
means ± SEM (n= 6, 6, 7, 7, 6, 6, 6. 6, 8, 7, 6, and 6 animals). 
 
Figure 8: Elimination of somatostatin expression from primary afferent neurons increases pain 
sensitivity.  
Sstf/f;Trpv1 cre mice are much more sensitive to noxious heat stimulation than normal littermate 
controls, A. In contrast, Sstf/f;Lbx1 cre mice exhibit similar withdrawal latency to noxious heat as 
normal littermate controls, B. Sstf/f;Wnt1 cre mice also display reduced latencies to noxious heat 
stimulation compared to normal littermate controls, C. Significant differences were assessed 
using two-sided unpaired Student t-tests (t20 = 4.156, t8 = 1.01, t12 = 4.059, *p = 0.0005, 0.3421, 
and 0.0016). Data represent means ± SEM (n= 11, 11, 5, 5, 7, and 7 animals). 
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Online Methods  
Animals 
Mice were 20-30g (2-4 months old) unless otherwise stated. The following lines: 
Ssttm2.1(cre)50, Ai3251, Ai952, PdynCre 53, nNOSCreERT2 50, Lbx1 cre54, Tg(Trpv1 cre)55, Wnt1 cre56, and 
Sst f/f (Sst tm1a (KOMP)) were bred and inter-crossed to generate experimental animals as described 
in the text. All experiments using mice followed NIH guidelines and were either approved by the 
National Institute of Dental and Craniofacial ACUC, or were approved by the Ethical Review 
Process Applications Panel of the University of Glasgow and performed in accordance with the 
UK Animals (Scientific Procedures) Act 1986. 
The targeted JM8A3 ES-cell clone F04 with knock-in insertion into the Sst gene was 
obtained from MBP UC Davis and was used to generate chimeric mice. Chimeras were crossed 
with C57BL6 and then with Gt(ROSA)26Sortm1(FLP1) mice to produce animals with a Cre-
dependent conditional Sst allele consisting of loxP sites surrounding exon 2. These mice were 
next crossed with Trpv1 cre, Wnt1 cre, and Lbx1 cre mice, to produce conditional knockout mice; 
controls were homozygous Sst f/f littermates without Cre. Age and sex matched Sst f/f cKO mice 
and littermates were used, and there were no significant phenotypic differences between sexes. 
Genotyping was performed with TGGTGAGATTATGAAGAGCAAGCG, 
GGCAGCTGTTCCCAATAGCCATC wild-type, and TGGTGAGATTATGAAGAGCAAGCG, 
ATCATTAATTGCGTTGCGCCATCTC, mutant alleles.  
Animals were maintained in a temperature-controlled environment with a 12-hour 
light/dark cycle and free access to food and water. Mice were group housed 4-5 animal per cage, 
except following surgical procedures when they were single housed. Unless otherwise noted, 
male C57BL/6N mice (Charles River) at least 6 weeks old were used for pharmacological and 
conjugated-peptide ablation studies.  
 
Optogenetic stimulation 
For light-mediated activation of trigeminal somatostatin neurons, Sstcre;Ai32 mice were 
implanted with a 200 µm diameter optical fiber (Thor labs) positioned within 1mm of the 
ganglion. Briefly, mice were anesthetized and mounted in a stereotaxic frame (Stoelting, USA). 
The skull was exposed and a hole drilled and fiber implanted with the following coordinates Z 
6.1 mm, X 1.2 mm, and Y 2.0 mm to Bregma. The cannula was secured using acrylic dental 
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cement and after the cement dried, the skin was trimmed and glued. Mice were allowed to 
recover and experiments were initiated approximately three weeks after surgery. 
To measure optogenetic-elicited behavior mice were placed in clear plastic enclosures 
with an optical cannula which could rotate to allow free movement of the mouse. Behavioral 
responses were recorded during the experiment. Mice were habituated for 30 min with the 
tethered optical cannula. Light was delivered from a Thorlabs LED driver (1000 mA, 20 Hz). For 
all animals, scratching bouts were counted for 30 minutes without illumination, followed by 30 
minutes with continuous 20 Hz 590 nm light, and finally, bouts were counted over 30 minutes 
with continuous 20 Hz 470 nm illumination. Counts of scratching bouts for individual animals 
were averaged over two sessions performed on consecutive days. Separate C57BL/6N mice were 
assessed for histamine-evoked scratching (10 μl injected into the cheek). 
For in vitro testing of the optogenetic excitation of somatostatin primary afferent neurons, 
DRGs from SstCre;Ai32 mice were incubated with 5mg/mL collagenase/Dispase for 30 minutes 
and were mechanically dissociated. Dissociated primary cultures were seeded onto poly-D-
Lysine treated cover slips. DRG neurons were cultured with Dulbecco's Modified Eagle 
Medium/F-12 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100µg/mL 
streptomycin, nerve growth factor (100ng/mL) and glial cell-derived neurotrophic factor 
(50ng/mL) for 2-4 days. Whole-cell recordings were performed on DRG neurons expressing 
channelrhodopsin-YFP with Axon 700B amplifier, 1440 Digitizer and pCLAMP 10 software 
(Molecular Devices). Bath solution contained 140mM NaCl, 4 mM KCl, 2mM CaCl2, 1mM 
MgCl2, 10mM HEPES. Pipette solution contained 140mM KCl, 10mM EGTA, 10mM HEPES, 
3mM Mg-ATP, 0.5mM Na-GTP. Light pulses were generated by Prizmatix blue LED fiber-
coupled LED light source and Prizmatix pulser in the following setting: 1Hz: 
25ms/975ms(on/off), 5Hz: 25ms/175ms, 20Hz: 25ms/25ms, 40Hz: 10ms/15ms.  
 
Chemogenetic activation   
Intraspinal injections were performed by using a modification of the method described by 
Foster et al31. Mice were anaesthetized with isoflurane and placed in a stereotaxic frame with 2 
vertebral clamps attached to the T12 and L1 vertebrae. The spaces between the laminae of T12-
T13 and T13-L1 vertebrae were exposed and a small incision was made in the dura on the right 
side of the midline in each space. A hole was drilled through the lamina of the T13 vertebra on 
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the right hand side and an incision was also made through the dura beneath this hole. Drilling a 
hole through the lamina of T13, rather than removing the lamina, was used to minimize swelling 
and distortion of the underlying spinal cord. Injections of 300 nl of the virus 
(AAV2.flex.hM3Dq-mCherry; University of North Carolina Vector Core; 7.7 x 108 GC in 300 nl 
of diluent) were made on the right hand side through each of these three incisions in the dura at a 
depth of 300 μm below the spinal cord surface and 400 μm lateral to the midline. To minimize 
leakage, the pipette was removed 5 minutes after the completion of each injection. Injections 
were made at a rate of 30 nl per minute with a 10 μl Hamilton syringe attached to a glass 
micropipette (inner tip diameter 40 μm) by using a syringe pump (Pump 11 Elite; Harvard 
Apparatus, Holliston, MA). The locations of the 3 injection sites described above were chosen to 
correspond to spinal segments L3, L4 and L5. Baseline behavioral tests (von Frey, Hargreaves, 
and Rotarod, see below) were performed 2 days before the operation, and further behavioral tests 
were carried out on two separate occasions (2 days apart) approximately 2 weeks after surgery. 
Mice were at least 6 weeks old when the post-operative behavioral tests were carried out. The 
first of these sessions involved intradermal injection of CQ into the calf and the Rotarod test, and 
the second session consisted of von Frey and Hargreaves tests. For the experiments involving 
nNOSCreERT2 mice, the animals received two IP injections of tamoxifen (3 mg tamoxifen in 0.15 
ml corn oil) on two consecutive days starting on the 3rd or 4th day after surgery. For each of the 
two post-operative behavioral testing sessions, mice were randomly assigned to CNO (CNO 
5mg/kg) or vehicle IP injection groups (random.org) and the experimenter was blind to treatment 
type. The assignment of mice to the treatment groups was independent for each behavioral 
session, so that an individual animal could receive either the same treatment (CNO or vehicle) or 
different treatments for the two sessions. Tests were performed between 1-5 hours after CNO or 
vehicle injections31. Thermal sensitivity was tested with a Hargreaves apparatus (IITC, 
Woodland Hills, CA, USA). Animals were acclimatized for 1 hour in a plastic cage on a glass 
plate warmed to 25°C and then a radiant heat source was targeted to the ipsilateral (right) hind-
paw 5 times with a 10 minute interval between each test. The time taken to lift the stimulated 
paw was measured. A cut-off time of 25 s was used to prevent tissue damage. Mechanical 
sensitivity was tested with von Frey hairs. Animals were acclimatized in a plastic cage with a 
wire mesh floor for 1 hour and then tested with von Frey filaments with logarithmically 
incremental stiffness (starting with 0.4g). Each filament was applied for 5 sec, and the presence 
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or absence of a withdrawal response was noted. The filament with the next incremental stiffness 
was then applied, depending on the response to the previous filament, and this was continued 
until there had been 6 positive responses. The filaments were applied to the glabrous skin on the 
right hind paw, and a positive response was recorded when there was lifting or flinching of the 
paw. The 50% withdrawal was determined by the up-down method57. To test for itch, mice were 
acclimatized for 2 hours in plastic observation chambers that were surrounded by mirrors such 
that the experimenter had an unobstructed view of the hind-limb15. We injected 100 μg 
chloroquine dissolved in 10 μl PBS intradermally into the front of the right calf, which had been 
shaved at least 48 hours previously. In each case, the success of the intradermal injection was 
confirmed by the presence of a bleb58. Mice were videorecorded for 30 mins after the CQ 
injection and the amount of time spent biting and licking the injection site was scored later 
offline. Motor co-ordination was tested by using a Rotarod (IITC) with the rod programmed to 
accelerate from 4 to 40 rpm over 5 mins. During the experimental testing session, the mice were 
allowed two trial runs followed by 4 test runs and the average of the maximum rpm tolerated was 
recorded. For each mouse, the ratio of maximum rpm during CNO/vehicle treatment over pre-
operative maximum rpm was determined. There was no significant difference in these ratios 
between CNO-treated and vehicle-treated mice in either the PdynCre or nNOSCreERT2 experiments 
(p = 0.1 and 0.29, respectively; two-sided t-test). Mice of both sexes were used in this part of the 
study, and no significant behavioral differences were observed between sexes. 
For intrathecal injections, we used the method described previously59 to administer 
AAV2.flex.hM3Dq-mCherry; 5.1 x 109 GC in 10 µl of saline. Mice were anesthetized with 
isoflurane. The caudal paralumbar region, just cranial to the iliac crests, was securely held by the 
thumb and middle fingers of the left hand, and the index finger was placed on the tip of sixth 
lumbar (L6) spinous process, the highest point of the vertebral column. All intrathecal injections 
were delivered in a total volume of 10 μl. The needle was inserted into the fifth intervertebral 
space (L5–L6) causing a sudden lateral movement of the tail. The needle was held in position for 
10 s and removed slowly to avoid outflow. Behavioral assays began 14 days after virus injection 
and animals were treated with 1mg/kg CNO60. One hour after CNO or vehicle injection, 
pruritogens were injected intradermally into the nape of the neck (histamine, or chloroquine), or 
delivered intrathecally (octreotide) and scratching bouts counted over 30 minutes.  
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Conjugated peptide-mediated cell ablation  
Ablation of Npr1- and GRPR-expressing spinal cord interneurons was accomplished by 
intrathecal (segment L3/4) injection of Nppb-saporin (4 µg in 10 µl; Advanced Targeting 
Systems) and GRP-saporin (2.5 µg) respectively. We have previously shown that these 
treatments are highly selective for the corresponding neuronal populations3. Behavioral assays 
were initiated two weeks after toxin injection.  
 
Itch Behavioral Test  
All other itch tests were performed as previously described3. Briefly, mice were 
habituated for 1 hour at room temperature in separate, clear, plastic containers (10 x 10 x 12 cm). 
The experimenter was blinded to genotype. Itch-inducing substances histamine, 100 µg, 
chloroquine, 100 µg, SLIGRL-NH2, 100 µg, 2-methyl serotonin, 30 µg, endothelin 25 ng, and 
compound 48/80, 100 µg were injected intradermally into the nape of the neck (10 µl) and 
numbers of scratching bouts directed to the nape of the neck assessed over 30 minutes. We 
cannot completely eliminate the possibility that we were observing nociceptive rather than 
pruritic behaviors, but since we used established pruritogens in these assays we interpret the 
scratching responses we measured as itch-behavior. Itch behavior was also elicited by lumbar 4-5 
vertebrae intrathecal injection of Nppb (5µg in 10µl), GRP (1 nmole in 10µl), and octreotide (10 
ng and 100 ng in 10µl as indicated in the text), all prepared in saline. Intrathecal pretreatment 
with GRP antagonist deamino-Phe19,D-Ala24,D-Pro26-D-Phe27-GRP (1 nM in 10 µl) was used 
to block the GRPR, Sst2-selective antagonist CYN 154806 (1µg in 10 µl) was used to block Sst2a 
receptor, the kappa-opioid receptor antagonist nor-binaltorphimine (nor-BNI, 100 ug in 10 µl) 
was used to block kappa-opioid receptor, and the kappa-opioid receptor agonist ICI 199441 
(0.1ug in 10 µl) was used to activate kappa-opioid receptor, all prepared in saline. We performed 
intrathecal injections with the same volume of dye solutions as we used in our assays, and 
observed staining of lumbar, thoracic, and cervical regions of the spinal cord, showing that this 
route of administration causes injected agents to spread along the entire spinal cord. The 
intrathecal administration of known pruritic agents, e.g. GRP and octreotide, predominantly 
resulted in scratching directed toward the nape of the neck and we observed only minor lower 
body evoked responses. Since the nape of the neck appears to be particularly sensitive to 
intrathecal administration, we recorded this behavior.  
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In Situ Hybridization  
Single and double label ISH was performed at high stringency as described previously3. 
The probe used to test Sst f/f mice corresponded to the entire exon2 of Sst. ISH experiments 
quantifying overlap of somatostatin with Nppb, and somatostatin with tdTomato were performed 
on 2-3 sections prepared from three wild-type and three SstCre;Ai9 mice respectively and 
representative images are displayed.  RNAscope, a multiplexed fluorescent in situ hybridization 
technique (Advanced Cell Diagnostics), was performed according to the manufacturer’s 
instructions on fresh frozen tissue sections. 
 
Behavioral testing of Sstf/f mice 
Thermal sensitivity was tested with a Hargreaves apparatus (Ugo-Basile). Animals were 
acclimatized for 1 hour in a plastic cage on a glass plate. A radiant heat source was targeted to 
the plantar surface of the hind-paw and withdrawal latency measured. A cut-off time of 20 s was 
used to prevent tissue damage. For von Frey measurements, mice were acclimatized in a plastic 
cage with a wire mesh floor for 1 hour and then tested with von Frey filaments with 
logarithmically incremental stiffness (starting with 0.4g). Each filament was applied for 5 sec, to 
the hind paw and the presence or absence of a withdrawal response was noted. The filament with 
the next stiffness was then applied, depending on the response to the previous filament, and this 
was continued until 6 positive responses were recorded. The 50% withdrawal was determined by 
the up-down method57. 
 
Immunocytochemistry for chemogenetic experiments 
All of the mice that had received intraspinal injections of AAV2.flex.hM3Dq-mCherry 
were deeply anaesthetised with pentobarbitone (30 mg i.p.) and perfused with 4% freshly 
depolymerized formaldehyde after completion of the behavioral experiments. The lumbar 
enlargement (L3-5 segments) was post-fixed for 2 hours and cut into parasagittal sections with a 
vibrating blade microtome. These were processed for immunocytochemical staining as described 
previously61. The sections were incubated in anti-mCherry (rabbit antibody, Abcam, ab167453, 
1:2000) for 3 days at 4°C and this was revealed with fluorescent-labelled species-specific 
secondary antibodies (Jackson Immunoresearch, West Grove, PA, USA). All antibodies were 
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diluted in phosphate-buffered saline containing 0.3% Triton-X100 and 5% normal donkey 
serum. Sections were scanned with a Zeiss LSM 710 confocal microscope to confirm adequate 
expression of the hM3Dq-mCherry fusion protein in the appropriate spinal segments. In rare 
cases intraspinal injections were not successful, as judged by lack of mCherry staining in the 
appropriate spinal segments, and in these cases the corresponding behavioral data were excluded 
from the study.  
In order to determine the neurochemical phenotype of neurons that expressed the 
mCherry fusion protein and to examine Fos staining following chemogenetic activation, a further 
5 mice of each genotype received intraspinal injections of AAV2.flex.hM3Dq-mCherry into the 
L3 and L5 segments. These mice were injected with either CNO (n=3 mice per genotype) or 
vehicle (n=2 mice per genotype), and two hours later they were perfused with fixative, as 
described above. Transverse spinal cord sections were cut from the L3 and L5 spinal segments. 
Sections from nNOSCreERT2 mice were immunostained for mCherry (chicken antibody Abcam, 
ab205402, 1:10,000), nNOS (rabbit antibody, Millipore, 07-571, 1:2000), Sst2a (guinea pig, 
Gramsch Laboratories, SS-870, 1:2000) and Fos (goat antibody, Santa Cruz biotech, sc52-G, 
1:2000). Sections from PdynCre mice were reacted for mCherry (chicken antibody), Sst2a, Pax2 
(rabbit antibody, Life Technologies, 716000, 1:1000) and Fos. Two sections from each mouse 
were analysed with Neurolucida software (MBF, Bioscience, Williston, VT, USA). All cells in 
the superficial dorsal horn (laminae I-II) that were mCherry-immunoreactive were identified. 
The stained neurons were then examined for the presence of the other markers. In addition, to 
determine the proportion of Fos cells that were mCherry-immunoreactive, we counted neurons 
that were Fos-positive but lacked mCherry. Note that for technical reasons we did not use 
antibodies against preprodynorphin (PPD) as our PPD antibody is raised in guinea pig, the same 
species as the Sst2a antibody, and in addition PPD may be below the detection threshold to allow 
unambiguous identification of all dynorphin-expressing neurons. 
Both mCherry antibodies were raised against recombinant full-length protein 
corresponding to mCherry. Specificity is demonstrated by the finding of an identical distribution 
of staining to that seen with native fluoresence of mCherry protein, and by the lack of staining in 
regions of tissue that do not contain mCherry. The Fos antibody was raised against a peptide 
corresponding to the N-terminus of human Fos, and its specificity has been shown in previous 
studies by the restriction of staining to neurons in somatotopically appropriate areas after 
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noxious or pruritic stimulation61. The nNOS antibody was directed against a synthetic peptide 
corresponding to N terminus of rat nNOS and labels a single band of 155 kDa in rat brain 
extracts. The antibody against Pax2 was raised against amino acids 188 to 385 of the mouse 
protein and recognizes bands of the appropriate size on Western blots of mouse embryonic 
kidney62. The Sst2a antibody was generated against the C terminal 15 amino acids of the mouse 
receptor, and staining is abolished by incubation with the immunizing peptide (manufacturer’s 
specification). 
 
Distribution of excitatory and inhibitory dynorphin cells 
Three wild-type C57BL/6 mice (either sex, 19-20 g) were perfused with fixative as 
described above. Spinal cord segments L3, L4 and L5 were removed from all 3 mice and C6, C7 
and C8 from 2 mice. In each case, the segments were cut into 4 sets of transverse sections, one of 
which was immunoreacted to reveal Pax2, PPD and NeuN, and one to reveal VGLUT3. The 
tyramide signal amplification method (TSA kit tetramethylrhodamine NEL702001, PerkinElmer 
Life Sciences, Boston, MA, USA) was used to reveal PPD and VGLUT3. Two or 3 sections that 
had been reacted with the first antibody combination were analysed by using a modification of 
the disector method13. All PPD-immunoreactive neurons with the bottom surface between 
reference and look-up sections were initially plotted onto an outline of the dorsal horn, and then 
the presence or absence of Pax2 staining was recorded for each selected cell. The sections that 
had been reacted with VGLUT3 antibody were then examined, and those that were closest in 
appearance to the sections analysed for PPD were scanned. The medial edge of the band of 
VGLUT3 staining, which represents hairy skin territory, was located and added to the outline 
drawing. The PPD antibody63 was raised against a peptide corresponding to amino acids 229–
248 at the C terminus of rat PPD, and has been shown to label PPD, but not dynorphin or 
enkephalin. The NeuN antibody was raised against cell nuclei extracted from mouse brain and 
found to react with a protein specific for neurons64, which has subsequently been identified as the 
splicing factor Fox-3. The antibody against VGLUT3 was raised against amino acids 522-588 of 
the mouse protein and detects a single protein band at 60-62 kDa. 
 
Somatostatin action on dynorphin cells 
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Eight PdynCre mice of either sex (18-23 g, aged 5-9 weeks) received intraspinal injections 
of AAV.flex.eGFP (4.3 × 108 - 1.7 × 109 GC in 300 nl diluent). These were performed as 
described above, except that injections were made through incisions on either side of the T13 
vertebra into the L3 or L5 segments, and the mice survived between 7 and 11 days after surgery.  
Five of these animals were used for electrophysiological experiments. The animals were 
decapitated under general anaesthesia with isoflurane (1-3%). Spinal cords were isolated in ice-
cold dissecting solution that contained the following (in mM): 3.0 KCl, 1.2 NaH2PO4, 0.5 CaCl2, 
1.3 MgCl2, 8.7 MgSO4, 26 NaHCO3, 20 HEPES, 25 glucose, 215 sucrose, oxygenated with 95 % 
O2 and 5 % CO2. The dura mater was removed, and ventral and dorsal roots were trimmed close 
to the cord. The lumbar segments containing the injection site were cut into parasagittal slices 
(300 μm) with a vibrating blade microtome (MicromHM 650V, Fisher Scientific). Slices were 
held in the dissecting solution at room temperature for at least 30 min, and then transferred into 
recording solution that contained the following (in mM): 126 NaCl, 3.0 KCl, 1.2 NaH2PO4, 2.4 
CaCl2, 1.3 MgCl2, 26.0 NaHCO3, 15 glucose, oxygenated with 95% O2, 5% CO2. GFP-positive 
cells found within the superficial dorsal horn (mostly lamina II) were targeted for whole-cell 
patch-clamp recording, under fluorescent and infrared differential interference contrast 
microscopy on an Olympus BX51WI microscope. Patch pipettes were pulled with a horizontal 
puller (P-97, Sutter Instruments) from glass capillaries (Harvard Apparatus). The pipettes 
typically had an electrical resistance of 4 - 6MΩ when filled with internal solution, which 
contained the following (in mM): 130 potassium gluconate, 10 KCl, 2 MgCl2, 10 HEPES, 0.5 
EGTA, 2 ATP-Na2, 0.5 GTP-Na, pH adjusted to 7.3 with 1 M KOH. Neurobiotin (0.2 %, Vector 
Laboratories) was also included in the internal solution for subsequent identification of recorded 
cells. Patch-clamp signals were amplified and filtered (4 kHz low-pass Bessel filter) with a 
MultiClamp 700B amplifier (Molecular Devices) and acquired at 10 kHz using a Digidata 1440 
A A/D board and pClamp 10 software (Molecular Devices). When whole-cell mode was 
established, the cell was presented with voltage and current step protocols to have its intrinsic 
membrane properties assessed. While holding the cell at -60 mV, voltage steps from -90 to -50 
mV (500 ms, 5 mV increments) were applied in order to allow the current-voltage (I-V) 
relationship to be obtained. In current-clamp mode, steps of square current pulse (1 s) were 
injected to evoke action potentials. Patterns of action potential firing were classified as described 
previously38. To minimize the chance of sampling excitatory interneurons we excluded cells that 
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showed delayed or gap firing patterns, which are associated with an excitatory phenotype38. 
Somatostatin (2 μM, Tocris Bioscience) was administered via the recording solution, and any 
change in membrane potential was recorded in current-clamp mode. Around 5 minutes after the 
start of somatostatin application, the same voltage and current step protocols were repeated to 
assess somatostatin-mediated modulatory effects in the recorded cell (n = 8).  
Three of the PdynCre mice that had received intraspinal injection of AAV.flex.eGFP were 
deeply anaesthetised and perfused with fixative. Injected spinal cord segments were removed and 
processed for immunocytochemistry as described above. Parasagittal sections were 
immunoreacted to reveal Sst2a, somatostatin (rabbit antibody, Peninsula labs, T-4103, 1:500) and 
VGLUT2 (chicken antibody, Synaptic systems, 135416, 1:500). Five eGFP+ cells that were Sst2a-
immunoreactive were selected from each mouse before immunostaining for somatostatin was 
observed, and these were scanned with a confocal microscope to include as much of the dendritic 
tree as was visible in the section. The cell bodies and dendritic trees were reconstructed with 
Neurolucida software based on eGFP fluorescence. The other channels were then viewed, and 
contacts from somatostatin+/VGLUT2+ boutons were marked. The VGLUT2 antibody was raised 
against a synthetic peptide corresponding to aminoacids 566-582 of rat VGLUT2 and detects a 
single band of appropriate molecular weight on Western blots (manufacturer's specification). The 
somatostatin antibody is reported to show 100% cross-reactivity with somatostatin-28 and 
somatostatin-25, but none with substance P or neuropeptide Y, and staining is blocked by 
preincubation with somatostatin65.  
 
Statistical analysis  
Data are expressed as mean ± SEM. Statistical analysis was performed in Prism 
(GraphPad). Differences between 2 groups were examined using a two-sided Student’s t test, 
with p<0.05 considered significant and p>0.05 considered non-significant. When comparisons 
were made between different groups of mice ANOVA was used and when repeated effects were 
assessed in a single group of mice (Figure 2 only) repeated measure ANOVA was used. No 
statistical methods were used to pre-determine sample sizes but our sample sizes are similar to 
those reported in previous publications 4,19,46. Data distribution was assumed to be normal but 
was not formally tested. Data collection was not randomized and data analysis and collection 
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were not performed blind to the conditions of the experiment except where noted (chemogenetic 
experiments). Animals and data points were not excluded from analysis. All relevant data are 
available from authors.  
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Supplementary Figure 1 
ISH analysis of the expression of Nmb, Gal, Tac1, Calca, Nppb, and Sst in the DRG. 
Triple label in situ hybridization was used to assess the numbers of neurons expressing genes for the
neuropeptides: A, neuromedin B (Nmb) and galanin (Gal); B, tachykinin 1 (Tac1, substance P) and calcitonin
gene related peptide (Calca); C, natriuretic polypeptide b (Nppb) and somatostatin (Sst) relative to the pan-
neuronal gene β3-tubulin (Tubb3). The fractions of neuropeptide expressing neurons were determined relative
to Tubb3-positive cells, D. Data are means ±SEM (n=3 animals, 3 sections per mouse). Mean cell counts for
each labeling experiment were, Nmb 855, Gal 215, and Tubb3 1400; Tac1 457, Calca 476, and Tubb3 1006; 
Nppb 92, Sst 89, and Tubb3 1059. 
Supplementary Figure 2 
Somatostatin-cre neurons innervate the skin and can be reliably activated using optogenetics. 
A, double label ISH reveals that in SstCre;Ai9 mice expression of tdTomato (tdT, magenta) occurs largely in
Nppb-neurons (green). White arrows indicate Nppb-expressing neurons not expressing tdTomato, and the grey
arrow indicates a tdTomato-positive neurons that does not express Nppb. Similar results were obtained from 3 
mice. B, Somatostain-neurons innervate superficial layers of the skin. A section through the ear of a Sstcre;Ai9 
mouse reveals tdTomato fibers (red) that are close to the surface of the skin (image is superimposed on a DIC-
image to highlight the location of fibers); also see1,2 for evidence of cutaneous segregation of somatostatin-
expressing afferents. C, Neurons from Sstcre;Ai32 mice can be optogenetically activated with a variety of 
frequencies of light stimulation. Cultured DRG-neurons from Sstcre;Ai32 were stimulated at 1, 5, 20, and 40 Hz 
and electrophysiological responses recorded under current (left panel), or voltage clamp (right panel)
conditions. n=11/11 neurons responding, all neurons exhibited non-saturating responses up to 20Hz. 
1. Molander, C., Ygge, J. & Dalsgaard, C.J. Substance P-, somatostatin- and calcitonin gene-related 
peptide-like immunoreactivity and fluoride resistant acid phosphatase-activity in relation to retrogradely 
labeled cutaneous, muscular and visceral primary sensory neurons in the rat. Neurosci Lett 74, 37-42 
(1987). 
2. O'Brien, C., Woolf, C.J., Fitzgerald, M., Lindsay, R.M. & Molander, C. Differences in the chemical 
expression of rat primary afferent neurons which innervate skin, muscle or joint. Neuroscience 32, 493-
502 (1989). 
 
Supplementary Figure 3 
Chemogenetic activation and transmitter phenotype in mCherry-labelled neurons. 
A. Immunostaining for Pax2 was used to define inhibitory cells among the mCherry-labelled neurons in the 
PdynCre mice and a mean of 97 (range 82-120) cells were analysed in sections from 5 mice. For the nNOSCreERT2
mice, Sst2a immunoreactivity was used to identify inhibitory mCherry+ neurons (mean 86 cells, range 72-120), 
because both Pax2 and nNOS antibodies were raised in rabbit. The proportion of mCherry neurons that were
Pax2-immunoreactive in PdynCre mice was 72.7% (62.9-90.2%), while the proportion of mCherry neurons that
were Sst2a-immunoreactive in the nNOSCreERT2 mice was 57% (45-67.1%). Similar results were obtained in 5 
mice of each genotype. B. In both PdynCre and nNOSCreERT2 mice the great majority of mCherry neurons were 
Fos+ after CNO treatment, irrespective of their neurotransmitter phenotype (95.9% [188/196] and 92.1%
[93/101], respectively, for inhibitory and excitatory mCherry cells in PdynCre mice and 98.2% [108/110] and 
86.1% [142/165], respectively, for inhibitory and excitatory mCherry cells in nNOSCreERT2 mice). Data were 
pooled from 3 CNO-treated mice of each genotype and absolute cell numbers are shown in square brackets.
Very few Fos+ cells were seen in vehicle-treated mice: 1.3% [2/154] and 5.7% [2/35], respectively for 
inhibitory and excitatory mCherry cells in PdynCre mice and 0% [0/63] and 1.1% [1/93], respectively, for 
inhibitory and excitatory mCherry cells in nNOSCreERT2 mice. Data were pooled from 2 vehicle-treated mice of 
each genotype and absolute cell numbers are shown in square brackets. Similarly, the majority of Fos+ cells 
were also mCherry-positive in both mouse lines in the CNO-treated mice: 84.6% [281/332] and 63.5 [251/395], 
respectively for the PdynCre and nNOSCreERT2 lines. Few Fos cells were seen in the vehicle-treated mice, and 
some of these were mCherry-positive: 19% [4/21] and 3% [1/33], respectively for the PdynCre and nNOSCreERT2
lines. Experiments were performed on 5 mice of each genotype, which had received intraspinal injections of
AAV2.flex.hM3Dq-mCherry into the L3 and L5 spinal segments. For each genotype, three of the mice were 
treated with CNO and two with vehicle two hours before perfusion fixation. Graphs show individual 
percentages for each of these mice. 
Supplementary Figure 4 
Laminar distribution of mCherry expression and lack of expression in dorsal root ganglia in PdynCre and 
nNOSCreERT2 mice that had received intraspinal injections of AAV2.flex.hM3Dq-mCherry. 
A-D show transverse sections through the rostral part of the L3 segment of a PdynCre mouse (A,B) and through
the caudal part of L3 of a nNOSCreERT2 mouse (C,D). In both genotypes, mCherry-positive cells form a dense
band in the superficial dorsal horn, and there are scattered neurons in deeper laminae of the dorsal horn,
consistent with the distribution of dynorphin- and nNOS-expressing neurons. Images to the right (B, D) show
mCherry-immunoreactivity superimposed on a dark-field image, which indicates the location of the gray matter.
Similar results were obtained from 5 animals of each genotype.  E-J show scans of L4 dorsal root ganglia from 
the right side (ipsilateral to the intraspinal injection) of PdynCre (E-G) and nNOSCreERT2 (H-J) mice. In each case, 
immunostaining for mCherry is shown on the left, a dark-field image in the middle and a merged image on the 
right. No mCherry-positive cells were observed in the DRGs in either strain. Scale bar = 200 μm. Similar results 
were obtained from 4 nNOSCreERT2 animals and from 2 PdynCre animals. The time spent licking the calf in 
response to intradermal injection of chloroquine (100 μg) was reduced following chemogenetic activation
(CNO) in PdynCre mice (K), whereas there was no effect on responses in nNOSCreERT2 animals (L). Significant 
differences were assessed using two-sided unpaired Student's t-tests (t21 = 2.82, *p = 0.0103; ns not significant, 
t23 = 1.2, p = 0.2422). Data represent means ± SEM (n=11, 12, 12, and 13 animals, for PdynCre treated with 
CNO and vehicle and for nNOSCreERT2 treated with CNO and vehicle, respectively). 
Supplementary Figure 5 
Dynorphin excitatory neurons are chemogenetically activated, these include vertical cells, and there is a
spatial segregation of inhibitory and excitatory preprodynorphin cells in glabrous and hairy skin
territories in the dorsal horn. 
A shows part of a transverse section of spinal cord taken from a PdynCre mouse that had been injected with 
AAV2-flex-hM3Dq-mCherry and treated with CNO 2 hours prior to perfusion fixation. A neuron in the outer
part of lamina II, which is marked with an asterisk (*), expresses hM3Dq-mCherry (mCh, red), and is also 
immunoreactive for Fos (green), showing that it was chemogenetically activated. This is a projection of 6
confocal optical sections at 2 μm z-spacing, to show details of the dendritic tree. Arrowheads indicate
prominent ventrally-directed dendrites, which are characteristic of vertical cells (a type of excitatory 
interneuron). The images on the right show the same cell in a projected image from only 2 optical sections. The
nucleus of this cell is negative for Pax2 (blue) confirming that this is an excitatory neuron (see Figure S3 for 
numbers). Scale = 20 μm. Similar results were obtained from 3 animals. We identified 17 mCherry-positive 
lamina II neurons with ventral dendrites that entered lamina III in the sections analysed (n = 5 mice) and found
that 16 of these (94%) were Pax2-negative (i.e. excitatory neurons). B. Excitatory dynorphin cells are largely
restricted to regions of the superficial dorsal horn that are innervated from glabrous skin. Plots of inhibitory
(Pax2-positive, blue circles) and excitatory (Pax2-negative, red circles) neurons that were immunoreactive for
preprodynorphin (PPD) in three segments from the cervical enlargement: C7, C8 and T1 (data pooled from 2
mice) are shown. For C7 and C8, the border between regions innervated by hairy and glabrous skin, determined 
by immunostaining for VGLUT3 (not shown), is indicated by a dashed line. The regions lateral and medial to
this line are innervated from hairy and glabrous skin, respectively. In the T1 segment, the VGLUT3 plexus
extended right across the mediolateral extent of the dorsal horn, indicating that the whole region was innervated
from hairy skin. C shows quantification of the of inhibitory and excitatory PdynCre neurons in the lumbar (L3,
L4, L5) and cervical (C7, C8, T1) enlargements. All cells illustrated in the plates in panel A and in Fig 5 are
included, and these have been divided into those in hairy and glabrous skin territories. Note that the proportions
of excitatory PPD cells differ significantly between hairy skin territory (11.1% for lumbar, 10.6% for cervical)
and glabrous skin territory (52.9% for lumbar, 62.8% for cervical). These differences were highly significant
(Fisher exact probability test, two-sided, p = 7.5 × 10-11 for cervical and 5.4 × 10-9 for lumbar). Lumbar and 
cervical enlargements therefore display similar differential distribution of excitatory and inhibitory PdynCre 
neurons in the medial and lateral dorsal spinal cord. Data for the lumbar and cervical enlargements were
obtained from 3 and 2 animals, respectively. 
Supplementary Figure 6 
Sstf/f; Trpv1cre and Sstf/f; Lbx1cre mice do not exhibit itch phenotypes. 
A, Sstf/f; Trpv1cre, and B, Sstf/f; Lbx1cre mice do not display significant differences in their scratch responses to
intra-dermal injection of a variety of compounds, compared to littermate controls. Data are means ±SEM (n= 7, 
8, 6, 6, 6, 6, 8, 8, 6, 6, 5, 6, 6, 6, 8, 8, 8, 9, 6, and 7); no significant (ns) difference in response were observed 
between genotypes assessed using two-sided unpaired Student t-tests (t13 = 0.5919, t10 = 0.3334, t10 = 1.703, t14
= 0.7476, t10 = 0.011, t9 = 1.565, t10 = 0.3265, t14 = 0.7429, t15 = 0.2209, t11 = 1.273, *p = 0.5641, 0.7457, 
0.1194, 0.4671, 0.9913, 0.1520, 0.7508, 0.4698, 0.8282, and 0.2292). C, testing with von Frey filaments
revealed significantly lower thresholds for reflex paw withdrawal responses for Sstf/f;Trpv1cre, Sstf/f;Lbx1cre and 
Sstf/f;Wnt1cre mice compared to control littermates, differences assessed using two-sided unpaired Student t-tests 
(t10 = 2.607, 2.507, 1.581, *p = 0.0262, 0.0311, and ns p = 0.1449). Data are means ±SEM (n= 6 animals). 
Supplementary Figure 7 
Response of dynorphin cells to somatostatin. Whole-cell patch clamp-recordings were made from eight
eGFP-positive neurons in spinal cord slices from PdynCre mice that had received intraspinal injections of 
AAV.flex.eGFP. 
A.An example trace showing membrane hyperpolarization in response to bath-applied somatostatin (2 μM) in a 
dynorphin cell. All 8 cells tested showed clear hyperpolarization within a few minutes of the start of
somatostatin application. B. Changes in the membrane potential of individual cells (circle, n = 8) are plotted,
and the mean values (gray bar ± SD) are shown in control conditions (-58.0 ± 5.2 mV) and in the presence of 
somatostatin (-67.4 ± 6.5 mV). Somatostatin caused statistically significant hyperpolarization (t7 = 3.935, p = 
0.0056, two-sided paired t-test, n = 8) in the dynorphin cells. C. Subthreshold currents measured in response to 
a voltage step protocol (-90 to -50 mV, 5 mV increments, 500 ms duration) while the cell was held at -60 mV 
under control conditions and in the presence of somatostatin. A reduction in the input resistance and an outward
shift of the measured current during somatostatin application are apparent in this example trace. D. A plot of the
values for each cell (circles, n = 8) before and during somatostatin application shows that all of the neurons
have their input resistance reduced during somatostatin application. The mean values (gray bar ± SD) are shown
for control (858.7 ± 380.7 MΩ) and somatostatin-treated conditions (516.9 ± 288.7 MΩ). A two-sided paired t-
test indicates that this effect is significant (t7 = 6.243, p = 0.00043). E. The current-voltage (I-V) relationship 
was plotted using the voltage step protocol (as in C) in control conditions and in the presence of somatostatin.
The I-V relationship in control conditions was then subtracted from that in the presence of somatostatin, which 
demonstrates the I-V relationship for the current responsible for the somatostatin-induced hyperpolarization.
This current appears to reverse at -80.6 mV, which suggests that activation of somatostatin receptors was
coupled to a downstream effect of opening G-protein coupled inwardly rectifying potassium (GIRK) channels.
This intracellular coupling mechanism was previously suggested for another population of sst2a-expressing 
inhibitory interneurons in the mouse superficial dorsal horn3. Data were obtained from 8 cells and are shown as
mean ± standard deviation. F. Patterns of action potential firing in control conditions (top) and during
somatostatin application (bottom). Action potentials were evoked by injecting square current pulses (1 s). Of
the 8 cells tested, 5 initially exhibited a tonic firing pattern while 3 cells showed an initial bursting pattern.
However, after somatostatin application, only 1 cell continued to show tonic firing and the remaining 7 cells
exhibited an initial bursting pattern. Note that the hyperpolarizing effect of somatostatin was counteracted by
adding bias currents to the recorded cell to restore the membrane potential to around -60 mV. This conversion 
in firing patterns after somatostatin application indicates that not only the resting membrane potential, but also
the ability of the cell to generate action potentials, was inhibited by somatostatin. G-I. Confocal optical section
through the cell body of one of the recorded neurons, showing expression of GFP (green) and avidin-rhodamine 
(magenta), which was used to detect Neurobiotin. The recorded cell is GFP+. J. The morphology of the cell seen 
in a projection of 55 optical sections at 1 μm z-separation. Scale bars I = 20 μm, J = 50 μm. 
3. Iwagaki, N., Garzillo, F., Polgar, E., Riddell, J.S. & Todd, A.J. Neurochemical characterisation of 
lamina II inhibitory interneurons that express GFP in the PrP-GFP mouse. Mol Pain 9, 56 (2013). 
Supplementary Figure 8 
Contacts from boutons that contain somatostatin and VGLUT2 onto dynorphin cells that express the 
sst2a receptor. 
A-C confocal image of part of a sagittal section from a PdynCre mouse that had received an intraspinal injection 
of AAV.flex.eGFP. eGFP is shown in green and sst2a receptor in magenta. Nine eGFP+ cells are present in this 
field, and 8 of these (marked with asterisks) are sst2a -immunoreactive, while 1 (arrowhead) lacks the receptor. 
Between 70 and 79 (mean 74.3) eGFP+ cells were identified in sections from the L3 segment of 3 mice, and 
78.2% (68.9-78.5%) of these were sst 2a-immunoreactive. This is consistent with our finding that 90% of lamina 
I-II preprodynorphin neurons in hairy skin territory are inhibitory, and that 91% of inhibitory PPD cells are sst 
2a-immunoreactive4. The box indicates the cell body of the neuron that is illustrated in D-I. D-I Contacts from 
boutons that co-express somatostatin (SST, red) and VGLUT2 (blue) onto the cell body (D-F) and dendrite (G-
I) of a eGFP+ cell that was immunoreactive for sst 2a (magenta in D). Contacts are indicated with arrows. J. Plot 
of the contacts from SST/VGLUT2 boutons onto the cell bodies (yellow circles) or dendrites (blue circles) of 5 
of the cells that were analysed. The top left cell is the one in illustrated in A (surrounded by box) and D-I. 
Confocal images in A-C are projected from 4 optical sections at 1 μm z-spacing. Those in D-F and G-I are 
projected from 3 and 5 (respectively) optical sections at 0.5 μm z-spacing. Scale bars: A-C = 50 μm, D-I = 5 
μm, J = 50 μm. 
4. Boyle, K.A. et al. A quantitative study of neurochemically defined populations of inhibitory
interneurons in the superficial dorsal horn of the mouse spinal cord. Neuroscience 363, 120-133 (2017). 
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